Middletown Life

Author: CervoMed Inc.

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

April 22, 2026
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

April 7, 2026
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology

March 19, 2026
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

March 17, 2026
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

March 12, 2026
CervoMed to Participate in Upcoming Investor Conferences

March 5, 2026
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

March 4, 2026
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

February 18, 2026